<\/a>
\n\t\t\t\t\t\t
\n\t\t\t\t\t<\/div><\/div><\/div>\n\t\t\tThe capital contribution \u2014the second one from Inveready and the first one from Fitalent\u2014 is in addition to public funding which the company obtained in 2011 as part of the Impact Program of the Ministry of Economy and Competitiveness. Genoma Espa\u00f1a, which invests in the third round through an equity loan, has been one of the main drivers of the company. <\/p>\n
In total, Palobiofarma, which researches and develops new drugs to improve quality of life for those suffering from neurodegenerative and respiratory diseases, has more than \u20ac2 millions to carry out their business plan in 2012 and 2013. <\/p>\n
Palobiofarma CEO Julio Castro manifested his satisfaction for “having found venture capital interested in investing in our business project, and even more now if we take into account that closing a round of funding right now was quite difficult. I think we’ve shown our capacity to generate competitive, high-quality projects with limited resources.” <\/p>\n
Beneficial properties of coffee<\/p>\n
<\/b> This Catalan biotech firm is basing its research on recent studies that have demonstrated that diseases like Parkinson, Alzheimer and asthma take longer to develop in people who drink coffee regularly. This is due to the interaction of the caffeine with the adenosine receptors, a molecule involved in important body functions like heart rate, memory, inflammatory processes and energy balance. <\/p>\n
After more than five years of research, and thanks to this recent injection of venture capital, Palobiofarma will begin phase I clinical trials on the adenosine A2a antagonist to treat Parkinson. This research will be key to reducing the side effects of drugs used to treat degenerative diseases, specifically the trembling and loss of coordination patients experience while being treated with Levodopa. In the first quarter of 2013, clinical trials will begin on a powerful adenosine A1 antagonist for oral treatment of asthma. <\/p>\n
These projects will be developed through to proof of concept in humans (phase II), which according to the company’s development plan will culminate in 2014 with the licensing of these products to pharmaceutical companies.<\/p>\n","protected":false},"excerpt":{"rendered":"
Genoma Espa\u00f1a and venture capital firms Fitalent \u2014whose benchmark partner is the Everis consultancy \u2014 and Inveready Seed Capital have invested \u20ac1 million in the biotechnology firm Palobiofarma, which is based in the Barcelona Science Park (PCB). The funds raised are integrated into the third round of funding for Catalan biotech, whose aim is to fund the Phase I clinical trials of the company’s two most advanced products for Parkinson’s disease and asthma treatments.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[8],"tags":[],"class_list":["post-47912","post","type-post","status-publish","format-standard","category-uncategorized"],"acf":[],"yoast_head":"\n
Genoma Espa\u00f1a, Fitalent and Inveready invest \u20ac1 million in Palobiofarma - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/en\/genoma-espana-fitalent-and-inveready-invest-e1-million-in-palobiofarma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genoma Espa\u00f1a, Fitalent and Inveready invest \u20ac1 million in Palobiofarma - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Genoma Espa\u00f1a and venture capital firms Fitalent \u2014whose benchmark partner is the Everis consultancy \u2014 and Inveready Seed Capital have invested \u20ac1 million in the biotechnology firm Palobiofarma, which is based in the Barcelona Science Park (PCB). The funds raised are integrated into the third round of funding for Catalan biotech, whose aim is to fund the Phase I clinical trials of the company's two most advanced products for Parkinson's disease and asthma treatments.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/en\/genoma-espana-fitalent-and-inveready-invest-e1-million-in-palobiofarma\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2012-06-14T23:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-11-18T13:52:25+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2020\/11\/1340291158817.jpg\" \/>\n<meta name=\"author\" content=\"adminpcb\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"adminpcb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/genoma-espana-fitalent-and-inveready-invest-e1-million-in-palobiofarma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/genoma-espana-fitalent-and-inveready-invest-e1-million-in-palobiofarma\\\/\"},\"author\":{\"name\":\"adminpcb\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"headline\":\"Genoma Espa\u00f1a, Fitalent and Inveready invest \u20ac1 million in Palobiofarma\",\"datePublished\":\"2012-06-14T23:00:00+00:00\",\"dateModified\":\"2020-11-18T13:52:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/genoma-espana-fitalent-and-inveready-invest-e1-million-in-palobiofarma\\\/\"},\"wordCount\":338,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/genoma-espana-fitalent-and-inveready-invest-e1-million-in-palobiofarma\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/1340291158817.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/genoma-espana-fitalent-and-inveready-invest-e1-million-in-palobiofarma\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/genoma-espana-fitalent-and-inveready-invest-e1-million-in-palobiofarma\\\/\",\"name\":\"Genoma Espa\u00f1a, Fitalent and Inveready invest \u20ac1 million in Palobiofarma - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/genoma-espana-fitalent-and-inveready-invest-e1-million-in-palobiofarma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/genoma-espana-fitalent-and-inveready-invest-e1-million-in-palobiofarma\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/1340291158817.jpg\",\"datePublished\":\"2012-06-14T23:00:00+00:00\",\"dateModified\":\"2020-11-18T13:52:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/genoma-espana-fitalent-and-inveready-invest-e1-million-in-palobiofarma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/genoma-espana-fitalent-and-inveready-invest-e1-million-in-palobiofarma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/genoma-espana-fitalent-and-inveready-invest-e1-million-in-palobiofarma\\\/#primaryimage\",\"url\":\"http:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/1340291158817.jpg\",\"contentUrl\":\"http:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/1340291158817.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/genoma-espana-fitalent-and-inveready-invest-e1-million-in-palobiofarma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genoma Espa\u00f1a, Fitalent and Inveready invest \u20ac1 million in Palobiofarma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\",\"name\":\"adminpcb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"caption\":\"adminpcb\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/adminpcb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Genoma Espa\u00f1a, Fitalent and Inveready invest \u20ac1 million in Palobiofarma - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/en\/genoma-espana-fitalent-and-inveready-invest-e1-million-in-palobiofarma\/","og_locale":"en_US","og_type":"article","og_title":"Genoma Espa\u00f1a, Fitalent and Inveready invest \u20ac1 million in Palobiofarma - Parc Cient\u00edfic de Barcelona","og_description":"Genoma Espa\u00f1a and venture capital firms Fitalent \u2014whose benchmark partner is the Everis consultancy \u2014 and Inveready Seed Capital have invested \u20ac1 million in the biotechnology firm Palobiofarma, which is based in the Barcelona Science Park (PCB). The funds raised are integrated into the third round of funding for Catalan biotech, whose aim is to fund the Phase I clinical trials of the company's two most advanced products for Parkinson's disease and asthma treatments.","og_url":"https:\/\/www.pcb.ub.edu\/en\/genoma-espana-fitalent-and-inveready-invest-e1-million-in-palobiofarma\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2012-06-14T23:00:00+00:00","article_modified_time":"2020-11-18T13:52:25+00:00","og_image":[{"url":"http:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2020\/11\/1340291158817.jpg","type":"","width":"","height":""}],"author":"adminpcb","twitter_card":"summary_large_image","twitter_misc":{"Written by":"adminpcb","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/en\/genoma-espana-fitalent-and-inveready-invest-e1-million-in-palobiofarma\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/en\/genoma-espana-fitalent-and-inveready-invest-e1-million-in-palobiofarma\/"},"author":{"name":"adminpcb","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"headline":"Genoma Espa\u00f1a, Fitalent and Inveready invest \u20ac1 million in Palobiofarma","datePublished":"2012-06-14T23:00:00+00:00","dateModified":"2020-11-18T13:52:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/genoma-espana-fitalent-and-inveready-invest-e1-million-in-palobiofarma\/"},"wordCount":338,"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/genoma-espana-fitalent-and-inveready-invest-e1-million-in-palobiofarma\/#primaryimage"},"thumbnailUrl":"http:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2020\/11\/1340291158817.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/en\/genoma-espana-fitalent-and-inveready-invest-e1-million-in-palobiofarma\/","url":"https:\/\/www.pcb.ub.edu\/en\/genoma-espana-fitalent-and-inveready-invest-e1-million-in-palobiofarma\/","name":"Genoma Espa\u00f1a, Fitalent and Inveready invest \u20ac1 million in Palobiofarma - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/genoma-espana-fitalent-and-inveready-invest-e1-million-in-palobiofarma\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/genoma-espana-fitalent-and-inveready-invest-e1-million-in-palobiofarma\/#primaryimage"},"thumbnailUrl":"http:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2020\/11\/1340291158817.jpg","datePublished":"2012-06-14T23:00:00+00:00","dateModified":"2020-11-18T13:52:25+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/en\/genoma-espana-fitalent-and-inveready-invest-e1-million-in-palobiofarma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/en\/genoma-espana-fitalent-and-inveready-invest-e1-million-in-palobiofarma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/en\/genoma-espana-fitalent-and-inveready-invest-e1-million-in-palobiofarma\/#primaryimage","url":"http:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2020\/11\/1340291158817.jpg","contentUrl":"http:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2020\/11\/1340291158817.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/en\/genoma-espana-fitalent-and-inveready-invest-e1-million-in-palobiofarma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"Genoma Espa\u00f1a, Fitalent and Inveready invest \u20ac1 million in Palobiofarma"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021","name":"adminpcb","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","caption":"adminpcb"},"url":"https:\/\/www.pcb.ub.edu\/en\/author\/adminpcb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/47912","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=47912"}],"version-history":[{"count":1,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/47912\/revisions"}],"predecessor-version":[{"id":52282,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/47912\/revisions\/52282"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=47912"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=47912"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=47912"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}